Mel Engle, CEO of ThermoGenesis [NASDAQ: KOOL] recently discussed with OneMedRadio, the company’s stem cell products and FDA approval that may have groundbreaking implications for the stem cell market.
OneMedForum NY 2011, to be held June 23 -24, has added new members to the Advisory Board and selected an initial group of “discovery” lesser known companies with terrific growth potential.
ThermoGenesis said its device, used in processing stem cells from bone marrow, got Indian marketing approval, sending its shares up as much as 8 percent.
Copyright © 2025 | WordPress Theme by MH Themes